Next 10 |
home / stock / argx / argx articles
July 18, 2024Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the live...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efg...
ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse for multifocal motor neuropathy (MMN...
Friday, the FDA approved Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo for use in patients with chronic inflammatory demyelinating polyneuropathy...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of RXO, Inc.. (NYSE:RXO) share...
VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (...
R&D Day presentations to include recent Phase 2 datasets in Sjogren's disease (efgartigimod) and multifocal motor neuropathy (empasiprub...
June 4, 2024Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 08:00:17 ET Leland Gershell from Oppenheimer issued a price target of $546.00 for ARGX on 2024-07-23 07:02:00. The adjusted price target was set to $546.00. At the time of the announcement, ARGX was trading at $461.01. The overall price target consensus is at ...
July 18, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, Ju...
First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study July 16, 2024 6:30am CET Amsterdam, the Netherlands— ...